Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00726713 · ClinicalTrials.gov registry record · Phase 4
Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)
A Phase 4 study, sponsored by Pamlab.
- Completed
- Registry status
- Phase 4
- Development phase
- 214
- Enrollment target
NCT00726713 is a Phase 4 study that has completed, run by Pamlab. The registered enrollment target is 214 participants.
The verdict
NCT00726713, a Phase 4 study, has completed, sponsored by Pamlab.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 214 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if Metanx improves sensory neuropathy in persons with Type 2 diabetes. Metanx is a medical food available with a prescription from a physician. It consists of L-methylfolate, Pyridoxal 5'-phosphate, and Methylcobalamin, which are the active forms of folate, vitamin B6, and vitamin B12, respectively. Subjects will be randomly assigned to receive either Metanx or placebo for 6 months.
Interventions
- OTHER Metanx (a medical food)
- OTHER Metanx placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00726713
The ClinicalTrials.gov registry entry for NCT00726713 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pamlab, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metanx (a medical food) is the first listed.
NCT00726713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00726713 about?
NCT00726713 is a clinical study titled "Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)". The purpose of this research study is to determine if Metanx improves sensory neuropathy in persons with Type 2 diabetes. Metanx is a medical food available with a prescription from a physician. It consists of L-methylfolate, Pyridoxal 5'-phosphate, and Methylcobalamin, which are the active forms of...
What is the current status of trial NCT00726713?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 214 participants. The study started on 2008-06. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00726713?
The interventions under investigation include: Metanx (a medical food) (OTHER), Metanx placebo (OTHER).
Who is sponsoring clinical trial NCT00726713?
This trial is sponsored by Pamlab, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.